- 期刊
- OpenAccess
Pharmacotherapies for COPD
並列摘要
This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines.
延伸閱讀
- Desai, H., & Dalal, B. (2012). Management Options in Chronic Obstructive Pulmonary Disease. Clinical Medicine Insights: Therapeutics, 2012(), 273-285. https://doi.org/10.4137/CMT.S6563
- Lau, W. L. (2001). Outcomes of COPD patients receiving long term oxygen therapy [master's thesis, The University of Hong Kong]. Airiti Library. https://www.airitilibrary.com/Article/Detail?DocID=U0029-1812201200000592
- 陳以雯、翁紹恩、李啓明、徐莞曾（2022）。Pharmacotherapy Principles and Pharmaceutical Care in Heart Failure。台灣醫學，26(1)，54-65。https://doi.org/10.6320/FJM.202201_26(1).0007
- 姚重光、翁銘偉（2020）。The Eosinophilic Inflammation in COPD。內科學誌，31(2)，67-82。https://doi.org/10.6314/JIMT.202004_31(2).02
- Rovina, N., Koutsoukou, A., & Koulouris, N. G. (2013). Inflammation and Immune Response in COPD: Where Do We Stand?. Mediators of Inflammation, 2013(), 296-304-127. https://doi.org/10.1155/2013/413735